The missense and heterozygous cancer-associated mutations typically occur at Arginine 132 in IDH1 and Arginine 172 in IDH2, impairing the ability of mutant IDH to bind with isocitrate (Yan et al., 2009; Pirozzi and Yan, 2021). This evidence concerns the gene IDH1 and cancer.